Shandong Boan Biotechnology (HKG:6955) obtained approval for a phase II clinical trial of its anti-CD25 antibody BA1106 from China's National Medical Products Administration.
The drug is being tested in combination with a PD-1 inhibitor BA1104 as first- or second-line regimen for non-small cell lung cancer, according to a Thursday filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.